Collaborative development of heart medication III trial did not meet primary endpoints, causing stock prices of AstraZeneca (AZN.US) and Ionis (IONS.US) to plummet.

Zhtng cijng APP huxn, slkng (AZN.US) y Ionis (IONS.US) linh kif de ykun shyn xng xnzngbng yow zi huq lnghu shyn zhng wi nng ddo zhyo lioxio zhngdin, gi g ln dn gupi gji zhusn bo di jn 10%, jizh fgo, zhusn mig pnqin di 8.67%, Ionis gji pnqin y xidi y 8%. According to the Zhitong Finance APP, a jointly developed experimental heart disease drug by AstraZeneca (AZN.US) and Ionis (IONS.US) did not meet the main efficacy endpoint in late-stage clinical trials. The London-listed stock price plummeted nearly 10% on Wednesday, and as of the time of writing, pre-market trading in the US on Wednesday fell by 8.67%, with Ionis' stock price also dropping more than 8% in pre-market trading.